Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R31 | P59538 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PNLIP | P16233 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Agathic Acid SCHEMBL21914839 | 1.00 | TAS2R31 (0.64) | TAS2R31POLBMAPTPTPN1CYP2C9 | |
| Agathic Acid SCHEMBL29358171 | 1.00 | TAS2R31 (0.64) | TAS2R31POLBMAPTPTPN1CYP2C9 | |
| SCHEMBL30436964 | 0.90 | POLB (0.58) | TAS2R31POLBMAPTPTPN1CYP2C9 | |
| Isocupressic Acid SCHEMBL13532265 | 0.89 | POLB (0.66) | TAS2R31POLBMAPTPTPN1CYP2C9 | |
| Isocupressic Acid SCHEMBL19139984 | 0.89 | POLB (0.66) | TAS2R31POLBMAPTPTPN1CYP2C9 | |
| Copalic Acid SCHEMBL25221800 | 0.89 | TAS2R31 (0.66) | TAS2R31POLBMAPTPTPN1LMNA | |
| Copalic Acid SCHEMBL29481956 | 0.89 | TAS2R31 (0.66) | TAS2R31POLBMAPTPTPN1LMNA | |
| Copalic Acid SCHEMBL34460866 | 0.89 | TAS2R31 (0.66) | TAS2R31POLBMAPTPTPN1LMNA | |
| SCHEMBL15214261 | 0.88 | POLB (0.64) | TAS2R31POLBMAPTPTPN1CYP2C9 | |
| SCHEMBL21914841 | 0.88 | TAS2R31 (0.63) | TAS2R31POLBMAPTPTPN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240389587-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING PHYTOPATHOGENIC INFECTIONS | INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE) (FR) | 2024-11-28 | — | — | US | disclosed |
| EP-4186367-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING PHYTOPATHOGENIC INFECTIONS | Institut national de recherche pour l'agriculture, l'alimentation et l'environnement (INRAE) (FR) | 2023-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240389587-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING PHYTOPATHOGENIC INFECTIONS | XBP1, ERN1, ERN2 | TAS2R31 3780/4885POLB 4124/4885MAPT 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.